Free Trial

Chromocell Therapeutics Q2 2024 Earnings Report

Chromocell Therapeutics logo
$1.45 +0.10 (+7.36%)
As of 03:54 PM Eastern

Chromocell Therapeutics EPS Results

Actual EPS
-$0.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Chromocell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Chromocell Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Chromocell Therapeutics Earnings Headlines

Brace Yourself for Jeff Bezos’ “Amazon Helios”
Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.
Chromocell Therapeutics Corp (CHRO)
Channel Therapeutics Corporation (CHRO)
See More Chromocell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chromocell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chromocell Therapeutics and other key companies, straight to your email.

About Chromocell Therapeutics

Chromocell Therapeutics (NYSE:CHRO), a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

View Chromocell Therapeutics Profile

More Earnings Resources from MarketBeat